Literature DB >> 32189074

Emergency Department and Inpatient Management of Headache in Adults.

Jennifer Robblee1, Kate W Grimsrud2.   

Abstract

PURPOSE OF REVIEW: This article reviews treatment options for patients presenting with headache in the emergency department (ED) and for inpatients, including red flags and status migrainosus (SM). RECENT
FINDINGS: Most patients presenting with headache in the ED will have migraine, but red flags must be reviewed to rule out secondary headaches. SM refractory to home treatment is a common reason for ED presentation or inpatient admission, but high-quality treatment evidence is lacking. Common treatments include intravenous fluids, anti-dopaminergic agents with diphenhydramine, steroids, divalproex, nonsteroidal anti-inflammatory drugs, intravenous dihydroergotamine, and nerve blocks. Other therapies (e.g., ketamine and lidocaine) are used with limited or inconsistent evidence. There is evidence for inpatient behavioral management therapy. This article details red flags to review in the workup of headache presentation in the ED and provides a step-wise approach to ED and inpatient management. However, more studies are needed to better optimize care.

Entities:  

Keywords:  Emergency; Headache; Inpatient; Migraine; Red flags; Status migrainosus

Year:  2020        PMID: 32189074     DOI: 10.1007/s11910-020-01030-w

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  89 in total

1.  Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.

Authors: 
Journal:  Cephalalgia       Date:  2018-01       Impact factor: 6.292

2.  The Use of a Pediatric Migraine Practice Guideline in an Emergency Department Setting.

Authors:  Courtney R J Kaar; James M Gerard; Albert K Nakanishi
Journal:  Pediatr Emerg Care       Date:  2016-07       Impact factor: 1.454

3.  Episodic status migrainosus: A novel migraine subtype.

Authors:  Tarun D Singh; F Michael Cutrer; Jonathan H Smith
Journal:  Cephalalgia       Date:  2017-01-05       Impact factor: 6.292

4.  Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine.

Authors:  Benjamin W Friedman; Leonid Garber; Andrew Yoon; Clemencia Solorzano; Andrew Wollowitz; David Esses; Polly E Bijur; E John Gallagher
Journal:  Neurology       Date:  2014-02-12       Impact factor: 9.910

5.  Ziprasidone as a Potential Abortive Therapy for Status Migrainosus.

Authors:  Eric C Landsness; Leo H Wang; Robert C Bucelli
Journal:  Neurohospitalist       Date:  2016-06-02

6.  Predictors of Prolonged Hospital Stay in Status Migrainosus.

Authors:  S Y Modi; D Dharaiya; A M Katramados; P Mitsias
Journal:  Neurohospitalist       Date:  2016-04-05

7.  EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.

Authors:  S Evers; J Afra; A Frese; P J Goadsby; M Linde; A May; P S Sándor
Journal:  Eur J Neurol       Date:  2009-09       Impact factor: 6.089

8.  Explicit diagnostic criteria for transient ischemic attacks to differentiate it from migraine with aura.

Authors:  Elena R Lebedeva; Natalia M Gurary; Denis V Gilev; Anne Francke Christensen; Jes Olesen
Journal:  Cephalalgia       Date:  2017-10-10       Impact factor: 6.292

9.  Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series.

Authors:  Clinton Lauritsen; Santiago Mazuera; Richard B Lipton; Sait Ashina
Journal:  J Headache Pain       Date:  2016-11-22       Impact factor: 7.277

10.  Short Term Oral Methylergonovine Maleate Prophylaxis for Status Migrainosus. Case Series and Review of Literature.

Authors:  Najiya Haque; Nauman Tariq
Journal:  Front Neurol       Date:  2019-03-20       Impact factor: 4.003

View more
  2 in total

1.  Intravenous lidocaine vs. NSAIDs for migraine attack in the ED: a prospective, randomized, double-blind study.

Authors:  Sultan Tuna Akgol Gur; Elif Oral Ahiskalioglu; Muhammed Enes Aydin; Abdullah Osman Kocak; Pelin Aydin; Ali Ahiskalioglu
Journal:  Eur J Clin Pharmacol       Date:  2021-09-16       Impact factor: 2.953

Review 2.  Beyond the Raskin Protocol: Ketamine, Lidocaine, and Other Therapies for Refractory Chronic Migraine.

Authors:  Jeffrey J Mojica; Eric S Schwenk; Clinton Lauritsen; Stephanie J Nahas
Journal:  Curr Pain Headache Rep       Date:  2021-12-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.